[{"address1": "195 Church Street", "address2": "16th Floor", "city": "New Haven", "state": "CT", "zip": "06510", "country": "United States", "phone": "203 304 2499", "website": "https://www.trevitherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.", "fullTimeEmployees": 33, "companyOfficers": [{"maxAge": 1, "name": "Ms. Jennifer L. Good", "age": 59, "title": "Co-Founder, CEO, President, Interim Principal Financial Officer & Director", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 987254, "exercisedValue": 0, "unexercisedValue": 1388915}, {"maxAge": 1, "name": "Dr. James V. Cassella Ph.D.", "age": 69, "title": "Chief Development Officer", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 671632, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thomas R. Sciascia M.D.", "age": 71, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1953, "fiscalYear": 2024, "totalPay": 551426, "exercisedValue": 0, "unexercisedValue": 41845}, {"maxAge": 1, "name": "Mr. Christopher  Galletta", "age": 46, "title": "Controller & Chief Accounting Officer", "yearBorn": 1978, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Katie  McManus", "title": "Communications Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Farrell  Simon Pharm.D.", "title": "Chief Commercial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Katherine  Takaki Ph.D.", "title": "Senior VP of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 11.17, "open": 11.16, "dayLow": 11.06, "dayHigh": 11.675, "regularMarketPreviousClose": 11.17, "regularMarketOpen": 11.16, "regularMarketDayLow": 11.06, "regularMarketDayHigh": 11.675, "payoutRatio": 0.0, "beta": 0.744, "forwardPE": -24.291666, "volume": 1815967, "regularMarketVolume": 1750303, "averageVolume": 2119510, "averageVolume10days": 1381170, "averageDailyVolume10Day": 1381170, "bid": 11.62, "ask": 11.69, "bidSize": 2, "askSize": 5, "marketCap": 1419918080, "fiftyTwoWeekLow": 2.36, "fiftyTwoWeekHigh": 11.675, "allTimeHigh": 11.675, "allTimeLow": 0.46, "fiftyDayAverage": 9.117, "twoHundredDayAverage": 6.76145, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1216924160, "profitMargins": 0.0, "floatShares": 90633642, "sharesOutstanding": 121776855, "sharesShort": 14589302, "sharesShortPriorMonth": 12090295, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.119799994, "heldPercentInsiders": 0.0072000003, "heldPercentInstitutions": 0.94804, "shortRatio": 7.17, "shortPercentOfFloat": 0.1388, "impliedSharesOutstanding": 121776855, "bookValue": 1.63, "priceToBook": 7.153374, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -47298000, "trailingEps": -0.42, "forwardEps": -0.48, "enterpriseToEbitda": -23.688, "52WeekChange": 2.8355262, "SandP52WeekChange": 0.19736934, "quoteType": "EQUITY", "currentPrice": 11.66, "targetHighPrice": 27.0, "targetLowPrice": 13.0, "targetMeanPrice": 20.6, "targetMedianPrice": 21.5, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 203884992, "totalCashPerShare": 1.674, "ebitda": -51372000, "totalDebt": 891000, "quickRatio": 22.153, "currentRatio": 22.425, "debtToEquity": 0.449, "returnOnAssets": -0.22825001, "returnOnEquity": -0.35742, "freeCashflow": -25926876, "operatingCashflow": -42684000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "TRVI", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 4.38675, "regularMarketPrice": 11.66, "shortName": "Trevi Therapeutics, Inc.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1557235800000, "postMarketChangePercent": 2.744423, "postMarketPrice": 11.98, "postMarketChange": 0.3199997, "regularMarketChange": 0.49, "regularMarketDayRange": "11.06 - 11.675", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2119510, "fiftyTwoWeekLowChange": 9.3, "fiftyTwoWeekLowChangePercent": 3.9406781, "fiftyTwoWeekRange": "2.36 - 11.675", "fiftyTwoWeekHighChange": -0.015000343, "fiftyTwoWeekHighChangePercent": -0.001284826, "fiftyTwoWeekChangePercent": 283.5526, "earningsTimestamp": 1763064000, "earningsTimestampStart": 1763064000, "earningsTimestampEnd": 1763064000, "earningsCallTimestampStart": 1754598600, "earningsCallTimestampEnd": 1754598600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.42, "epsForward": -0.48, "epsCurrentYear": -0.4, "priceEpsCurrentYear": -29.15, "longName": "Trevi Therapeutics, Inc.", "cryptoTradeable": false, "fiftyDayAverageChange": 2.5430002, "fiftyDayAverageChangePercent": 0.2789295, "twoHundredDayAverageChange": 4.89855, "twoHundredDayAverageChangePercent": 0.7244822, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "corporateActions": [], "postMarketTime": 1761954544, "regularMarketTime": 1761940801, "exchange": "NGM", "messageBoardId": "finmb_225357348", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Trevi Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-01"}]